[Carcino-embryonic antigen as screening protein in the follow-up of patients with surgically-treated gastrointestinal cancer (author's transl)].
Carcino-embryonic antigen (CEA) was determined in 206 patients with gastrointestinal cancer (131 colonic and 75 stomach) at the 2nd Department of Surgery of the University of Vienna. The value of CEA in predicting tumour recurrence and/or metastatic spread has been assessed within the framework of regular follow-up control examinations after surgery. A postoperative rise in CEA titre corresponded with cancer recurrence or metastasis both in patients with stomach (91%), as well as colonic cancer (86%), whilst low postoperative CEA values correlated with a negative clinical report only in patients with carcinome of the colon to any degree of accuracy (91%). The correspondence was much lower in patients with stomach cancer (67%).
D002272:Carcinoembryonic Antigen / Q000032:analysis*; D003110:Colonic Neoplasms / Q000175:diagnosis; D005770:Gastrointestinal Neoplasms / Q000601:surgery*; D006801:Humans; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D011379:Prognosis
D002272:Carcinoembryonic Antigen
Das karzinoembryonale Antigen als Screeningprotein in der Nachkontrolle chirurgisch behandelter Patienten mit gastrointestinalem Karzinom.